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ABSTRACT
The identification of perineural invasion (PNI) and extraprostatic extension (ECE) 
in prostate cancer (PC) biopsies is time consuming and can be difficult. Although this 
is required information in many datasets, there is little evidence on their effect on 
outcome in patients treated conservatively. Cases of PC were identified from three 
cancer registries in the UK from men with clinically localized prostate cancer diagnosed 
by needle biopsy from 1990–2003. The endpoint was prostate cancer death (DOD). 
Patients treated radically within 6 months, those with objective evidence of metastases 
or who had prior hormone therapy were excluded. Follow-up was through cancer 
registries up until 2012. Deaths were divided into those from PC and those from other 
causes, according to WHO criteria. 988 biopsy cases (6522 biopsy cores) were centrally 
reviewed by three uropathologists and assigned a Gleason score and Grade Group (GG). 
The presence of both PNI and ECE was recorded. Of 988 patients, PNI was present in 288 
(DOD = 75) and ECE in 23 (DOD = 5). On univariable analysis PNI was highly significantly 
associated with DOD (hazard ratio [HR] 2.28, 95% CI: 1.68, 3.1, log-rank test p-value = 
4.8 × 10–8), but ECE was not (log-rank test p-value = 0.334). On multivariable analysis 
with GG, serum PSA (per 10%), clinical stage and extent of disease (per 10%), PNI lost 
significance (HR 1.16, 95% CI: 0.83, 1.63, likelihood ratio test p-value = 0.371). The 
utility of routinely examining prostate biopsies for ECE and PNI is doubtful as it is not 
independently associated with higher grade, stage or prognosis. 
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INTRODUCTION
In spite of the fact that prostate cancer is the fourth 
most common cancer globally and the second most 
common cancer in men there remains uncertainty on the 
optimal management strategy for clinically localized tumors 
of low and intermediate grades. Increasing detection has led 
to many men who are more likely to die with their prostate 
cancer than of it. The identification of clinicopathological 
or other biomarkers which are risk factors for progression 
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is therefore of great importance. Prostate cancer is 
diagnosed primarily by biopsy, and many factors have 
been used to predict the likelihood of progressive disease 
and need for radical therapy. Gleason score and recently 
the establishment of Grade Groups by the International 
Society of Urological Pathology [1] allows reasonable 
risk stratification, together with serum PSA, clinical stage 
and more recently imaging. Perineural invasion (PNI) by 
prostate cancer has long been considered a risk factor for 
disease progression.
Perineural invasion (PNI) is defined as “cancer 
tracking along or around a nerve within the perineural 
space”. Guidance from individual countries differs on 
whether PNI identification should be mandatory. While the 
Royal College of Pathologists requires reporting of PNI 
[2], the College of American Pathologists and International 
Collaboration on Cancer Reporting has suggested it is 
optional [3]. 
Many conflicting studies have been performed 
examining PNI in prostate cancer but the vast majority use 
either pathological surrogates or biochemical recurrence 
rather than prostatic cancer death as an outcome. None 
have been performed using prostate cancer death as an 
endpoint in patients with biopsies, who were initially 
treated in a conservative manner (Table 1). 
More rarely invasion of fat is seen in prostate 
biopsies. As fat is essentially absent from the prostate, any 
such case can be designated as extra prostatic extension 
(EPE), and TNM stage pT3 at least and may potentially 
assist in decisions for treatment. We wished to examine 
the hypothesis that assessments of PNI and extraprostatic 
invasion on a well characterized cohort with contemporary 
Grade group assessments, PSA and clinical stage added 
to the prognostic model and would help in decisions on 
active surveillance.
RESULTS
Of 988 patients, PNI was present in 288 (DOD = 75) 
and EPE in 23 (DOD = 5). Both were highly associated 
with GG (Pearson’s χ1² p-value ≤ 2.2 × 10
–16 and 5.1 × 
10–7), respectively, and strongly associated with each other 
(Pearson’s χ1² p-value = 2.8 × 10
–9). Table 1 compares 
death from prostate cancer in the PNI positive and 
negative groups. On univariable analysis PNI was highly 
significantly associated with DOD (HR 2.28, 95% CI: 1.68, 
3.1, log-rank test p-value = 4.77 × 10–8), but EPE was not 
(log-rank test p-value = 0.334). The median (interquartile 
range) for number of biopsies examined per case was 6 
(8–5). Kaplan-Meier survival curves of PNI groups were 
plotted for the entire TAPG-needle patients (Figure 1).
Table 2 shows the results of univariable and 
multivariable statistical analyses of the cohort, by time to 
death from prostate cancer as outcome (Supplementary 
Table 1). On multivariable analysis with GG, serum 
PSA (per 10%), clinical stage and extent of disease 
(per 10%), PNI lost significance (HR 1.16, 95% CI: 
0.83, 1.63, p-value = 0.371). However, PNI was the most 
informative predictor in GG 3 group (HR 2.20, 95% CI: 
1.26, 3.86, log-rank test p-value = 0.005). However, PNI 
lost significance in combined GGs 1 and 2 as well as in 
combined GGs 4 and 5 (HR 1.65, 95% CI: 0.91, 3.0, log-
rank test p-value = 0.098) and (HR 1.14, 95% CI: 0.69, 
1.88, log-rank test p-value = 0.606) respectively (Figure 2). 
DISCUSSION
A systematic review [4] in 2007 was conducted to 
examine the utility of reporting PNI in prostate cancer 
specimens. This found that study design, execution, and 
reporting precluded meta-analysis and quantitative risk 
estimation. Since then a large number of papers have been 
published on PNI, but very few which use prostate cancer 
death as the outcome. Many studies, even those in the 
recent literature, use pathological factors as surrogates for 
outcome [5–8]. Others use progression usually defined by 
biochemical recurrence [9–11] or metastasis [12]. 
Saeter et al. [13] demonstrated that the prognostic 
effect of PNI is dependent on an association with high 
grade carcinoma and reactive stroma. Most of the available 
studies are on patients treated by radical prostatectomy 
[14–19], some of which use preoperative biopsy data while 
other use pathological data from the radical prostatectomy 
specimen. Two studies used prostatic biopsy to predict 
death after external beam radiotherapy [20, 21]. To our 
knowledge only three previous studies have examined PNI 
in patients treated conservatively. 
Moreira et al. [22] investigated 302 patients treated by 
active surveillance using disease progression as a surrogate 
for outcome. They showed that PNI was associated with a 
73% chance of clinical progression after 2 years. Cohn et 
al. [23] examined 165 men similarly showed PNI predicted 
progression in both univariate and multivariate analysis. In 
neither case was survival data available. 
Zareba et al. [24] investigated 615 men who 
underwent watchful waiting as part of the Swedish 
watchful waiting cohort. These men were diagnosed 
by trans-urethral resection of the prostate and not by 
biopsy. They showed that although PNI was significant in 
univariable analysis, this was not significant when adjusted 
for Gleason grade and tumor volume. 
The studies examining PNI and prostate cancer 
death are summarized in Table 3. Seven out of 12 of 
these studies has failed to show any significance of the 
identification of PNI on multivariate analysis. 
The challenges in looking for PNI are many, 
especially on biopsy specimens. Firstly, there may be 
no nerves for assessment in the biopsy. Only a relatively 
superficial biopsy of the prostate will contain nerves. 
The presence or absence of nerves in a biopsy is not 
regularly recorded, due to the difficulty in identification 
and laborious nature of this process. Therefore a ‘negative’ 
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result in a biopsy containing prostate cancer may either 
indicate that nerves were present without invasion, or that 
no nerves were identified. This could be facilitated by 
immunochemistry [25], but would be far too expensive 
and time consuming to make it a viable proposition. It is 
interesting to note that PNI may be more easily observed 
by multiparametric guided MRI than by non-guided 
biopsies [26]. This may make assessment of PNI for active 
surveillance more of a viable proposition prospectively. 
Examination for PNI itself is also very time 
consuming and in most busy pathology practices, it would 
seem to be wasteful of pathological time to examine every 
case for PNI where adequate risk stratification has already 
occurred. 
We have shown, in keeping with other studies that 
PNI is a univariable risk factor for prostate cancer death, 
and have shown this is seen in a biopsy cases where 
the amount of material examined is far less than radical 
prostatectomy or TURP specimens. However the strength 
of this association was much attenuated in multivariable 
analysis with other standard clinic-pathological variables. 
In practical terms, the main method by which the 
identification of PNI might be clinically helpful beyond 
providing prognostic information, is in setting the criteria 
for active surveillance. Pathology plays a central role in 
terms of defining eligibility [27]. 
One study, dealt with the significance of PNI on 
needle biopsy in patients who are candidates for AS [28] 
Table 1. Death from prostate cancer in GG and PNI Groups
Grade Group
Alive/DOC Death from Disease
Total
PNI negative PNI positive Sum PNI negative PNI positive Sum
1 276 16 292 15 0 15 307
2 177 87 264 23 16 39 303
3 100 58 158 26 26 52 210
4 27 14 41 5 10 15 56
5 26 38 64 25 23 48 112
Sum 606 213 819 94 75 169 988
Figure 1: Kaplan–Meier survival estimate for patients with PNI versus patients without PNI. 
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Table 2: Summary of statistical analysis of TAPG-needle cohort, by death from prostate cancer (univariable and 
multivariable Cox models); Harrell’s c-index (95% CI) = 0.768 (0.722, 0.815)
Univariable Multivariable
Predictor N (N-event)
Hazard ratio 
(95% CI)
likelihood ratio χ² 
(df, P) c-index
Hazard ratio (95% 
CI)
likelihood ratio χ² 
(P)*
Grade group 988 (169) 110.116 (4, <2 × 10–16) 0.732 110.116 (4, <2 × 10–16)
1 307 (15) 1 (reference) 1 (reference)
2 303 (39) 2.81 (1.55, 5.10) 1.96 (1.05, 3.66)
3 210 (52) 6.05 (3.40, 10.76) 3.34 (1.78, 6.28)
4 56 (15) 7.12 (3.48, 14.57) 4.09 (1.93, 8.70)
5 112 (48) 12.67 (7.09, 22.64) 5.16 (2.63, 10.12)
PSA (per 10%) 988 (169) 1.24 (1.18, 1.31) 51.827 (1, 6.1 × 10–13) 0.684 1.08 (1.01, 1.15) 13.844 (1, 0.0002)
% disease (per 10%) 988 (169) 1.25 (1.19, 1.32) 78.437 (1, <2 × 10–16) 0.704 1.08 (1.01, 1.15) 10.020 (1, 0.0015)
T-stage 988 (169) 58.487 (3, 1.24  × 10–12) 0.650 8.599 (3, 0.035)
Stage 1 136 (15) 1 (reference) 1 (reference)
Stage2 476 (54) 1.46 (0.81, 2.64) 1.04 (0.57, 1.89)
Stage 3–4 146 (55) 5.76 (3.18, 10.41) 1.87 (0.99, 3.55)
Stage-not recorded 230 (45) 2.07 (1.13, 3.78) 1.29 (0.69, 2.40)
PNI 26.676 (1, 2.4 × 10–07) 0.601
PNI-negative 700 (94) 1 (reference) 1 (reference)
PNI-positive 288 (75) 2.28 (1.68, 3.10) 1.16 (0.83, 1.63) 0.802 (1, 0.371)
Age (years) 988 (169) 1.03 (0.997, 1.06) 3.165 (1, 0.075) 0.527
ECE 0.805 (1, 0.370) 0.505
ECE-negative 965 (164) 1 (reference)
ECE-positive 23 (5) 1.55 (0.63, 3.76)
LR X2 = 143.380 (d.f. = 10, p < 2 × 10–16)
 *Terms added sequentially (first to last).
Figure 2: Forest plot of the PNI stratified by GG groups for time to DOD.
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but pathological surrogates for outcome were used. Cases 
with PNI had significantly greater likelihood of having 
more than 2 positive cores but showed no significant 
difference in surgical margin involvement or T3 disease at 
later radical prostatectomy or organ-confined disease. We 
therefore suggest that PNI should not currently be used to 
exclude from active surveillance protocols. 
It has been suggested that extra-prostatic extension 
can be assessed on some prostate biopsies where the 
margins of the prostate have been sampled and invasion 
of fat assessed [29]. More recent studies have shown the 
presence of rare small fat foci within the prostate often 
mixed with benign glands [30, 31]. However in most cases 
it should be possible to distinguish extraprostatic fat from 
foci within the prostate to perineural invasion. As EPE 
was identified on only on 29/988 cases (2.9%) this study 
was not well powered and failed to reach significance. 
However in prognostic terms identification of EPE appears 
not to be important in this series. We therefore suggest 
it remain an optional item for reporting in pathological 
datasets. The strengths of this study include the large 
cohort size, the use of outcome data and the centralized 
nature of the pathology review. Weaknesses include the 
nature of the cohort data from routine medical notes and 
the fact that while conservatively treated, the patients 
were not treated to current standards of imaging or active 
surveillance protocols. 
We suggest that examining prostate biopsy 
specimens for PNI is probably unnecessary, and that 
PNI remain a recommended rather than required part 
of national and International datasets. Its use as a 
potential exclusion criterion in patients entered for active 
surveillance is questionable and prospective studies using 
modern active surveillance strategies in conjunction with 
modern imaging are required for validation.
MATERIALS AND METHODS
Patients
Patient selection and data collection has been 
described in Cuzick et al., 2015 [32]. In short, prostate 
cancer cases were identified from three cancer registries 
in Great Britain. Case notes were reviewed within 
collaborating hospitals. Patients were included in the 
study if they were diagnosed by needle biopsy at age 
less than 76 and had clinically localized prostate cancer 
between 1990 and 2003 inclusively. Patients were excluded 
if they were treated with either radical prostatectomy or 
radiation therapy within 6 months of diagnosis. Patients 
were also excluded if they had either objective evidence 
of metastatic disease (as detected by pelvic lymph node 
dissection, lymph node biopsy, bone biopsy, MRI, CT scan, 
radiograph or bone scan), or clinical evidence of metastatic 
disease (such as bone pain, spinal cord compression, soft 
tissue metastases, or pathological fracture). Other exclusion 
criteria included a PSA measurement of >100 ng ml–1 
at or within 6 months of diagnosis, hormone therapy 
given prior to diagnostic biopsy, men who died within 6 
months of diagnosis and men who had less than 6 months 
of follow-up. The study median follow-up time was 9.66 
years with IQR 11.320–6.899.
Tissue specimens from the original needle biopsy 
were obtained and reviewed centrally by three specialist 
uropathologists to confirm diagnosis of adenocarcinoma 
and reassign Gleason score and Grade Group (GG). 
Table 3: Summary of studies which have examined perineural invasion as a prognostic factor in localized prostate 
cancer with prostate cancer death as the primary outcome 
Author Sample Type
Study 
size
Follow up 
(years) Treatment
Univariable 
significance of PNI 
Multivariable
significance of PNI
Saeter et al. Biopsy 318 10 Any  Yes No 
Tollefson et al. Biopsy 451 12.9 RP Yes Yes
DeLancey et al. Biopsy 3226 NR RP Yes Yes 
Feng et al. 2011 Biopsy 651 5.2 EBRT Yes Yes
Beard et al. 2004 Biopsy 517 4.5 EBRT Yes No
Aaltomaa et al. 2006 RP 211 NR RP Yes No
Andersen et al. RP 535 7.4 RP Yes Yes
Lee et al. RP 361 3.5 RP No No
Van den Ouden RP 273 4.1 RP No No
Zareba et al. (a) TURP 615 9 WW Yes No
Zareba et al. (b) RP 849 23 RP Yes Yes
Parameshwaran et al. Biopsy 988 9.52 WW/Hormones Yes No
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Patients were followed up to the 31st of December, 2012 
through the cancer registries. Deaths were defined as 
either those due to prostate cancer (DOD) and those due to 
other causes by registry staff using death certificates only, 
in keeping with World Health Organization standardized 
criteria. The Northern Multicenter Research Ethics 
Committee provided national ethical approval, followed 
by local ethics committee approval at each collaborating 
hospital. 
Statistical method
Univariable and multivariable analysis was 
performed using a Cox proportional hazards model with 
the primary end point of analysis defined as death from 
prostate cancer. Observations stopped either on the date 
of death from other causes (DOC) or on the date of last 
follow-up. Co-variables included in the statistical analysis 
were GG, baseline PSA value (per 10%), clinical tumor T 
stage, % of tumor disease (expressed as cancer-positive 
cores out of total number of cores), and presence of PNI 
and ECE. Grade group analysis on this cohort has also 
been previously published [33]. Statistical analyses were 
performed using R [34]. 
There were three missing PSA values which were 
imputed using a median regression with patient’s age as 
a predictor and PSA as an outcome. All statistical tests 
were two-sided. No adjustment for multiple comparisons 
was made. P-values and 95% CI were based on likelihood 
ratio χ2 statistic with one degree of freedom obtained from 
partial likelihoods of proportional hazard models unless 
stated otherwise. 
Abbreviations
CI: confidence interval; DOD: prostate cancer 
death (death of disease); DOC: death from other causes; 
ECE: prostatic extension; GG: grade group; HR: hazard 
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perineural invasion; PSA: prostate specific antigen; UK: 
United Kingdom; WHO: World Health Organization. 
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